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Pulmonary adenocarcinoma (PAC) is the leading type of lung
cancer in smokers and non-smokers that arises in most cases from
small airway epithelial cells. PAC has a high mortality due to its
aggressive behavior and resistance to cancer therapeutics. We
have shown previously that the proliferation of human PAC cells
NCI-H322 and immortalized human small airway epithelial cells
HPL1D is stimulated by cyclic adenosine monophosphate
(cAMP)/protein kinase A-dependent phosphorylation of cyclic
adenosine monophosphate response element-binding (CREB)
protein and transactivation of the epidermal growth factor re-
ceptor and that this pathway is activated by beta-1-adrenorecep-
tors (b1-ARs) and the non-genomic estrogen receptor beta. Our
current in vitro studies with HPL1D and NCI-H322 cells showed
that signaling via the gamma-amino butyric acid receptor (GA-
BABR) strongly inhibited base level and isoproterenol-induced
cAMP, p-CREB, cyclic adenosine monophosphate response
element-luciferase activity and p-extracellular regulated kinase-1
(ERK1)/2 andeffectivelyblockedDNAsynthesisand cellmigration.
The inhibitory effects of gamma-amino butyric acid (GABA) were
disinhibited by the GABABR antagonist CGP-35348 or GABABR
knockdown. Immunohistochemical investigation of hamster lungs
showed signiﬁcant underexpression of GABA in animals with
small airway-derived PACs induced by the nicotine-derived car-
cinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK).
These ﬁndings suggest that GABA may have tumor suppressor
function in small airway epithelia and the PACs derived from
them and that downregulation of GABA by NNK may contribute
to the development of this cancer in smokers. Our ﬁndings suggest
that marker-guided treatment with GABA or a GABABR agonist
of individuals with downregulated pulmonary GABA may provide
a novel targeted approach for the prevention of PAC in smokers.
Introduction
Pulmonaryadenocarcinoma (PAC)isanaggressivecancerwithamor-
tality near 100%within 5 years of diagnosis. The majorityof PACs are
thought to arise from small airway epithelial cells while alveolar type
II cells and mucin-producing cells may be the origin of small subsets
of PAC (1,2). The incidence of PAC continues to rise in smokers and
non-smokers (3) and this malignancy predominates in women.
The epidermal growth factor receptor (EGFR) is frequently over-
expressedin PAC and interferencewith its signaling pathway by small
molecule tyrosine kinase inhibitors has been the focus of intense re-
search. While these agents have shown great promise in preclinical
studies, they have disappointed in clinical trials (4–6). Studies by our
laboratory have identiﬁed an important role of cyclic adenosine
monophosphate (cAMP) signaling in the growth regulation of human
small airway epithelial cell line HPL1D and in the human PAC cell
line NCI-H322 (7), both of which express the bronchiolar Clara cell-
speciﬁc CC10 antigen. Classic agonists for beta-1-adrenoreceptors
(b1-ARs) or the tobacco-speciﬁc lung carcinogen 4-(methylnitrosa-
mino)-1-(3-pyridyl)-1-butanone (NNK), a high afﬁnity agonist for
this receptor (8), stimulated DNA synthesis in both cell lines via
cAMP-dependent signaling. The resulting activation of protein kinase
A (PKA) transactivated the EGFR and its downstream effectors while
additionally phosphorylating the transcription factor cyclic adenosine
monophosphate response element-binding (CREB) protein (7). Estro-
gen enhanced the responses to b1-AR signaling by non-genomic
cAMP signaling via the estrogen receptor beta (9). This cooperation
between b1-AR and estrogen receptor beta signaling may contribute
to the prevalence of PAC in women. Small airway-derived PACs in-
duced in Syrian golden hamsters by NNK overexpressed b-ARs
and their downstream effectors, PKA, p-CREB, p-EGFR, raf-1 and
p-extracellular regulated kinase-1 (ERK1)/2 (10,11). A beta-blocker
had signiﬁcant cancer preventive effects in this animal model (12). On
the other hand, treatment of the animals with the stress hormone
epinephrine, a physiological b-AR agonist, had signiﬁcant tumor-
promoting effects on NNK-induced PAC in hamsters (12). Epinephrine
or its precursor norepinephrine has also been shown to stimulate the
migration of adenocarcinoma of the prostate (13), colon (14), mam-
mary gland (15), stomach (16) and ovary (17). It hence appears that
hyperstimulation of cAMP-mediated signaling in response to b-AR
stimulation by stress hormones or NNK contribute to the aggressive
behavior of some of the most common solid human cancers, all of
them are adenocarcinomas. While antagonists for b-ARs (beta-blockers)
have shown signiﬁcant antitumorigenic effects in preclinical studies of
adenocarcinoma of the lungs (12), prostate (13), colon (14) and breast
(15), their clinical use for the prevention and treatment of human adeno-
carcinomas is problematic. Beta-blockers have signiﬁcant cardiovascular
effects and their chronic use results in the sensitization of b-ARs, ren-
dering these receptors more sensitive to agonists.Accordingly, long-term
treatment with such agents may promote the development and progres-
sion of cancers under positive growth control by cAMP signaling.
In search for a more suitable agent capable of counteracting hyper-
active cAMP signaling, our current study has focused on the neuro-
transmitter gamma-amino butyric acid (GABA). GABA is the major
inhibitory neurotransmitter in the central nervous system and controls
the excitatory effects of cAMP signaling by inhibiting adenylyl cy-
clase via activation of the inhibitory G-protein (Gai)-coupled gamma-
amino butyric acid receptor (GABABR) (18). GABA and its receptors
are also expressed in most non-neuronal tissues, including the lungs
(19). Our data provide evidence, for the ﬁrst time, that GABA is
underexpressed in NNK-induced small airway-derived PACs. In ad-
dition, our invitro data show that GABABR signaling strongly inhibits
cAMP-dependent signaling in human small airway epithelial and PAC
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tively blocking DNA synthesis and cell migration while the inhibitory
effects of GABA are disinhibited by GABABR knockdown.
Materials and methods
Immunohistochemical assessment of GABA in hamster lung tissues
Archived tissue blocks of lungs from 10 control hamsters and from 10 hamsters
with NNK-induced PACs (2.5 mg per 100 g three times per week for 20 weeks
bysubcutaneousinjection)thatwerereportedpreviouslytooverexpressthebeta-
adrenergic signaling pathway were used. This dosing regimen of NNK repro-
ducibly results in the development of PAC in this animal species at an incidence
of 80–100%. PACs were diagnosed by histopathology and are in accordance
with the lung tumor classiﬁcation (20) recommended as criteria for lung adeno-
carcinomas in the mouse (lesions comprised cuboidal to columnar cells, .5m m
in diameter, locally invasive). The sections were deparafﬁnized in xylene, dehy-
drated with graded ethanols, washed with phosphate buffered saline (PBS,
pH 7.4) and incubated with 0.3% hydrogen peroxide in 50% methanol for
20 min at room temperature. Immunostains were conducted using the Vectastain
Universal kit (Vector Laboratories, Burlingame, CA) according to the vendor’s
instructions. Incubations with primary antibody (polyclonal anti-GABA, Sigma,
St Louis, MS; 1:1000 dilutions) were performed in a humid chamber at 4C
overnight. Sections exposed to diluent alone without primary antibody served as
negative controls. The speciﬁcity of the GABA antibody was veriﬁed by pre-
incubation of the primary antibody with 200 lM GABA. This pre-incubation
completely abolished the positive immunoreactivity to GABA (Figure 1A).
Diaminobenzidine served as substrate and Mayer’s hematoxylin as counterstain.
The sections were photographed with a digital camera and analyzed densito-
metrically using National Institutes of Health (NIH) Scion image analysis soft-
ware. Brieﬂy, each photograph was zoomed to 200%, yielding a magniﬁcation
of  400. Densitometric analysis in a rectangular unit area of 0.5   0.3 cm was
performed in the cytoplasm of small airway epithelial cells, alveolar cells or
tumor cells with 100 measurements per cell type per hamster. To ensure ran-
domization of the measured areas, a clear plastic overlay with a grid was taped
over the computer screen and meeting points of horizontal with vertical grid
lines were selected for the measurements. Data were analyzed by one-way
analysis of variance (ANOVA) and Tukey–Kramer multiple comparison test.
Cell culture
The immortalizedhumansmallairwayepithelialcelllineHPL1Dwasa kindgift
from Dr Takahashi (21) and was maintained at 37C in Ham’s F12 medium
supplemented with 1% fetal calf serum, 5 lg/ml insulin, 5 lg/ml human trans-
ferrin, 50 nM hydrocortisone hemisuccinate, 4.75 pM 3,3#,5#-triiodo-L-
thyronine and 50 nM Na-selenite. The human PAC cell line NCI-H322 was
purchased from European Collection of Cell Cultures (Health Protection
Agency, Porton Down, Salisbury, Wiltshire, UK) and maintained in RPMI-
1640 culture medium (Gibco, Frederick, MD) supplemented with fetal bovine
serum (10% vol/vol) at 37C in an atmosphere of 5% CO2. All assays were
conductedinbasalmediawithoutsupplementsfollowingthreewasheswithPBS.
Assessment of DNA synthesis by BrdU incorporation assays
Bromodeoxyuridine (BrdU) incorporation assays were conducted with a kit
(Roche Applied Science, Indianapolis, IN) according to the vendor’s instruc-
tions as described previously (9). Cells were cultured in 96-well plates
(1   104 per well) deprived of serum and supplements for 24 h and then
treated with isoproterenol (10 nM) with and without pre-incubation (4 h) with
GABA or the selective GABABR agonist baclofen (30 lM; Sigma) for 72 h or
they were exposed to each of the inhibitors alone for the duration of the assay.
Cells were labeled with 10 ll per well BrdU and re-incubated at 37C for 4 h.
After removal of the labeling medium, cells were ﬁxed and probed with anti-
BrdU monoclonal antibody and its substrate, tetramethylbenzidine for 1 h. The
absorbance of each samplewas measured in an enzyme-linked immunosorbent
assay reader at 370 nm. A blank was run in each experiment to provide in-
formation about BrdU and anti-BrdU non-speciﬁc binding. The non-speciﬁc
binding was subtracted from all other values. Each experiment was conducted
twicewith ﬁve replicates per data point. Statistical analysis of data was by one-
way ANOVA and Tukey–Kramer multiple comparison tests.
Determination of cell migration
The metastasis of cancer cells is facilitated by their ability to migrate. Mea-
surement of cell migration is therefore frequently used as a tool to assess the
metastatic potential of cancer cells. A colorimetric cell migration assay kit
(Cell Biolabs, San Diego, CA) consisting of 24-well plates that contain poly-
carbonate membrane ﬁlter inserts (8 lM pore size) was used according to the
vendors’s instructions. Cells (0.5   106 cells/ml of basal medium) were
seeded onto the top chamber above the ﬁlter insert and pretreated for 4 h with
GABA (30 lM) or baclofen (30 lM). Isoproterenol (10 nM) was then added.
Following a 24 h incubation period, non-migratory cells were removed from
the top of the ﬁlters by cotton swab. The ﬁlter with cells that had migrated to its
bottom surface were incubated with staining solution for 10 min, washed three
times with tap water, air-dried and photographed. Following extraction of each
ﬁlter, optical density at 560 nm was read with a plate reader. Each assay was
conducted in triplicate. Statistical analysis of data was by ANOVA and Tukey–
Kramer multiple comparison tests.
Determination of intracellular cAMP by immunoassays
Cells were plated in complete medium at 4   105 cells per six-well plate and
grown until 65–70% conﬂuence. The cells were washed with PBS and main-
tained in basal medium without additives for 24 h. Following two washes with
PBS, the cells were then pre-incubated for 30 min with 1 mM isobutylmethyl-
xanthine (IBMX) (Sigma) and then exposed to isoproterenol (10 nM) in the
presence and absence of pre-incubation with GABA (30 lM) or baclophen (30
lM) in PBS in fresh basal medium containing 1 mM IBMX for 30 min. After
three washes with distilled water, cells were treated with 0.1 M HCl for 20 min
and then lysed by sonication. After centrifugation, samples were analyzed for
cAMP levels using a direct cAMP enzyme immunoassay kit according to the
manufacturer’s instructions (Assay Designs, Ann Arbor, MI). Color intensity
was measured at 405 nm. Statistical analysis of data was by one-way ANOVA,
Tukey–Kramer multiple comparison test and two-tailed unpaired t-test.
Fig. 1. Photomicrographs (magniﬁcation:  200) of hamster lung tissues
showing positive immunoreactivity to anti-mammalian GABA (brown stain)
in a control animal (B) and a hamster (C) treated for 20 weeks with NNK.
Figure (A) demonstrates the speciﬁcity of the primary antibody by lack of
immunoreactivity on a section from a control animal incubated with primary
anti-GABA antibody after preabsorption with GABA (200 lM).
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1980Assessment of phosporylated ERK1/2 and CREB proteins by western blots
NCI-H322 or HPL1D cells were seeded into culture vessels (500 000 cell per
100 cm2) containingtheir respective growth media.When the cells had reached
60–65% conﬂuence, they were rinsed one time with 1  PBS and starved of
serum and supplements for 24 h. Following removal of the media and replace-
ment with fresh basal media, isoproterenol (10 nM) was added in the presence
or absence of pre-incubation with GABA (30 lM for 30 min) or baclophen
(30 lM for 30 min) and cells were incubated for 10 min. Pre-incubation with
the selective GABABR antagonist CGP-35348 (30 lM for 30 min; Sigma) was
used to conﬁrm the involvement of the GABABR in the observed inhibitory
effects of GABA. The cultured cells were then washed once with cold PBS,
lysed in 20 mM Tris–base, 200 mM NaCl, 1 M sodium ﬂuoride. 0.5 M ethyl-
enediaminetetraacetic acid, 100 mM Na3VO4, 100 mM phenylmethylsulfonyl
ﬂuoride, 1 ml pepstatin, 1 ml leupeptin, 1 ml aprotinin and 0.25 % NP-40.
Then, protein samples were denatured by boiling at 95C for 5 min, separated
on 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis and trans-
ferred to nitrocellulose. Membranes were blocked with 5% non-fat dry milk,
probed with CREB and p-CREB or ERK1/2 and p-ERK1/2 antibodies, re-
spectively, and developed by chemiluminescence with enhanced chemilumi-
nescence reagents. Densitometry of the bands was performed using NIH Scion
software. Brieﬂy, the ﬁlms were scanned onto a computer screen and ﬁve
densitometric readings per band were taken. Data are expressed as meanvalues
and standard errors of the ratios of p-CREB/CREB (Figure 4B) or p-ERK1/2
(Figure 6A and B). Each experiment was repeated twice and yielded similar
results. Statistical analysis of data was by one-way ANOVA, followed by
Tukey–Kramer multiple comparison test and two-tailed unpaired t-test.
Transient transfection with stealth select RNAi for GABABR1
Cells (.90% viable) were plated at 3   104 cells per well in 24-well plates in
complete medium without antibiotics and allowed to reach 60% conﬂuence.
They were then transfected in triplicate for each treatment group with 100 llo f
40 nM of GABABR1 Stealth RNAi (Invitrogen, San Diego, CA) complexed
with 2 mg/ml Lipofectamine (Invitrogen). Following a 24 h incubation in
a humidiﬁed incubator (5% CO2,3 7 C), transfection efﬁciency, transfection
toxicity and percent of transfected cells were determined (Block-iT Alexa
Fluor Red Fluorescent Control, dead cell stain ethidium homodimer-1, nuclear
stain Hoechst 33342; Invitrogen). The growth medium was then replaced by
basal medium without additives and responses to isoproterenol, NNK and
GABA assessed in untransfected cells versus cells with GABABR knockdown,
using the cyclic adenosine monophosphate response element (CRE)-luciferase
reporter assay desribed below. Negative stealth RNAi provided by the vendor
served as negative control.
Assessment of CRE activation by CRE-luciferase reporter assay
Cells were cotransfected with 500 ng of pRSV-b-galactosidase and 1 lgo f
CRE-luciferase DNAs, alone, or along with 40 nM GABABR small interfering
ribonucleic acid (siRNA) constructs. Forty-eight hours after transfection, cells
were deprived of serum for 18 h before stimulation with the indicated agents.
Untransfected and transfected cells with control siRNA provided by the vendor,
either stimulated with the same agents or left alone, served as controls. Cells
were harvested 24 h later, and luciferase and b-galactosidase activities were
then measured using standard luciferase (Promega, Madison, WI) and b-ga-
lactosidase detection kits (Applied Biosystems, Bedford, MA).
Results
In accord with the role of GABA as a ubiquitous neurotransmitter,
immunohistochemical analysis of lung tissues from control hamsters
showed prominent positive immunoreactivity to GABA in all cells,
Fig. 2. Densitometry data of the immunostains with primary anti-GABA
antibody showing mean values and standard errors of 100 densitometry
readings from randomly chosen cytoplasmic areas (0.5   0.3 cm on
photographs enlarged to  400) of small airway epithelia, alveolar epithelia
or tumor cells per hamster from 10 hamsters. Data signiﬁcantly (P , 0.001)
different from small airway epithelial controls are identiﬁed by asterisk.
Fig. 3. Results of BrdU incorporation assays (A) and cell migration assays
(B) in the PAC cell line NCI-H322 and immortalized human small airway
epithelial cells HPL1D. Isoproterenol signiﬁcantly (P , 0.001) stimulated
each cell line in both assays and these responses were completely blocked by
GABA or baclophen. Data in (A) are mean values and standard deviations of
ﬁve replicates per data point. Data in (B) are mean values and standard
deviation from three separate assays with identical treatment groups. The
inset in (B) shows a photograph of the ﬁlter inserts with cells that have
migrated to the bottom surface of the ﬁlters. Data signiﬁcantly (P , 0.001)
different from controls are identiﬁed by asterisk in both graphs.
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1981including the lining cells of large and small airways, as well as lung
parenchyma, including alveolar epithelia and connective tissues
(Figure 1B). Positive immunoreactivity to GABA was completely
abolished when the primary anti-GABA antibody was preabsorbed
with GABA (Figure 1A), thus verifying the speciﬁcity of the antibody.
In addition, immunostains of lung sections exposed to diluent without
primary antibody yielded no detectable immunoreactivity (data not
shown). Positive immunoreactivity to GABAwas reduced in all lung
cells of animals treated with NNK, with PAC cells showing the stron-
gest reduction (Figures 1C and 2). The differences inGABA reactivity
between control and NNK-exposed airway epithelia (P , 0.001) or
lung parenchyma (P , 0.001) were signiﬁcant. In addition, the NNK-
induced PACs (Figures 1C and 2) demonstrated ,40% of the GABA
reactivity than the control small airway epithelial cells (P , 0.001).
These data suggest that NNK reduces GABA signaling in the lungs
and prompted us to explore a potential tumor suppressor function of
GABA by in vitro experiments.
As Figure 3A shows, the selective agonist for b-ARs, isoproterenol,
signiﬁcantly (P , 0.001) stimulated DNA synthesis in the human
PAC cell line NCI-H322 and in immortalized human small airway
epithelial cells HPL1D. This response was suppressed signiﬁcantly
(P , 0.001) below base levels by pretreatment of the cells with
GABA or the selective GABABR agonist baclophen (Figure 3B). Both
of these agents also signiﬁcantly (P , 0.001) reduced DNA synthesis
below the levels of untreated cells when administered alone. In addi-
tion, isoproterenol signiﬁcantly (P , 0.001) increased the number of
migrated NCI-H322 cells in cell migration assays (Figure 3B), a re-
sponse completely blocked by pretreatment of the cells with GABA or
baclophen. Again, both agents signiﬁcantly (P , 0.001) reduced base
level migration below the levels of untreated cells when administered
alone (Figure 3B).
The b1-AR is a member of the G-protein-coupled receptor family
that increases intracellular cAMP upon agonist-induced activation of
the stimulatory G-protein Gas. We have shown previously that the
tobacco carcinogen NNK, which is a high afﬁnity agonist for this
receptor (8), induces cAMP-dependent activation of PKA and CREB,
resulting in the stimulation of DNA synthesis in HPL1D and NCI-
H322 cells (7). In accord with these ﬁndings, immunoassays for the
detection of intracellular cAMP revealed a 6.4-fold (HPL1D) and
8.3-fold (NCI-H322) increase in cells exposed to isoproterenol
Fig. 4. Results of cAMP assays (A) showing strong stimulation by isoproterenol in HPL1D and NCI-H322 cells, responses completely blocked by GABA or
baclophen. Data are meanvalues and standard deviations of triplicate samples. Western blots (B) showing strong induction of p-CREB by isoproterenol in HPL1D
and NCI-H322 cells. This responsewas completely blocked by GABA or baclophen while the GABABR antagonist CGP-35348 disinhibited the effects of GABA.
Data in the graphs are mean values and standard deviations of ﬁve densitometric readings per band. Data signiﬁcantly (P , 0.001) different from controls are
identiﬁed by asterisk in both graphs.
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of the cells with GABA or baclophen (Figure 4A). Both of these
agents also signiﬁcantly (P , 0.001) reduced base levels of cAMP
in cells not exposed to isoproterenol (Figure 4A).
The transcription factor CREB is a classic downstream effector of
cAMPsignaling thatis activated by cAMP-dependent PKA. Wethere-
fore assessed the modulation of phosphorylated CREB protein in
HPL1D and NCI-H322 cells by western blots. As Figure 4B shows,
both cell lines responded to isoproterenol with a signiﬁcant
(P , 0.001) induction of p-CREB protein, an effect completely
blocked by pre-exposure of the cells to GABA or baclophen
(P , 0.001). The inhibitory effects of GABA on isoproterenol-
induced p-CREB induction were disinhibited by pretreatment of the
cells with the selective GABABR antagonist CGP-35348. These ﬁnd-
ings conﬁrm an important role of the GABABR in the observed in-
hibitory effects of GABA that are additionally suggested by the
almost identical responses of cells to GABA and the selective
GABABR agonist baclophen.
Phosphorylation of CREB at the Ser133 site is an important step in
the activation of genes with the CRE sites in their promoters. We
therefore studied the modulation of CRE activity by CRE-luciferase
reporter assays in HPL1D and NCI-H322 cells. As Figure 5A and B
shows, isoproterenol as well as NNK signiﬁcantly (P , 0.001) in-
creased CRE activity and simultaneous exposure of HPL1D and NCI-
H322 cells to both agents had signiﬁcant (P , 0.001) additiveeffects.
Pretreatment of the cells with GABA completely blocked the re-
sponses to isoproterenol or NNK while also signiﬁcantly (P , 0.001)
reducing the responses to the additive stimulation of isoproterenol and
NNK (Figure 5A and B). GABABR knockdown disinhibited the in-
hibitory effects of GABA in cells simultaneously stimulated by iso-
proterenol and NNK (Figure 5A and B). These ﬁndings further
emphasize the involvement of the GABABR in the observed effects
of GABA.
We have shown previously that treatment of HPL1D or NCI-H322
cells with a classic b-AR agonist or NNK activates the ERK1/2 cas-
cade via PKA-dependent transactivation of the EGFR (7). We there-
fore assessed the effects of GABA and baclophen on the expression of
p-ERK1/2 in isoproterenol-stimulated and untreated HPL1D and
NCI-H322 cells. As Figure 6A and B shows, isoproterenol signiﬁ-
cantly (P , 0.001) induced ERK1/2 phosphorylation in both cell
lines. This response was completely blocked by pretreatment of the
cells with GABA or baclophen while the GABABR antagonist CGP-
35348 disinhibited the effects of GABA (Figure 6A and B).
Discussion
Our data provide evidence, for the ﬁrst time, that the tobacco-speciﬁc
nitrosamine NNK signiﬁcantly reduces GABA in the lungs and that
small airway-derived PACs induced by this potent lung carcinogen
express particularly low levels of this inhibitory neurotransmitter.
These ﬁndings are in accord with investigations by proton magnetic
resonance studies that have revealed a reduction of GABA in the brain
of smokers (22). While the mechanisms how NNK reduces tissue
GABA levels remain obscure, our in vitro data indicate that GABA
suppresses the proliferation and migration of human PAC cells and
small airway epithelial cells via inhibition of base level and b-AR-
stimulated cAMP signaling. The observed isoproterenol-induced in-
crease in ERK1/2 phosphorylation and its inhibition by GABA and
baclophen are consistent with our reports of PKA-dependent EGFR
transactivation in these cells (7,9). Similarly, the observed additive
effects of NNK and isoproterenol in the CRE-luciferase assays is in
accord with the tumor-promoting effect of classic b-AR agonists on
NNK-induced PAC in hamsters (12).
Pharmacological or genetic silencing of the GABABR disinhibited
the effects of GABA. These ﬁndings indicate that the observed in-
hibitory effects of GABA were mediated by the GABABR and are
consistent with the documented ability of this receptor to inhibit
cAMP signaling via Gai-induced inhibition of adenylyl cyclase
(23–25). Collectively, these ﬁndings suggest that GABA may have
tumor suppressor function in these cells and that its downregulation
by NNK may contribute to the development and aggressive behavior
of PAC in smokers.
As our current and published (7,9) in vitro data show, cAMP/PKA
signaling has strong stimulatory effects on DNA synthesis and migra-
tion of human PAC cells with features of small airway epithelial cells.
We have also shown that, this signaling pathway is activated by NNK
and that it also stimulates the proliferation of the putative cells of
origin for most PACs, small airway epithelial cells (7,9). The emerg-
ing novel concept of NNK-induced impaired GABA-ergic tumor sup-
pressor function and concomitant hyperstimulation of cAMP
signaling that drives cell proliferation and migration of these PACs
goes far beyond a simple cause and effect model of lung cancer
initiation by the mutational activities of this tobacco carcinogens
and its reactive metabolites (26–28).
While we (7–9) and others (29,30) have unequivocally shown that
NNK stimulates b-adrenergic signaling in PAC and their cells of
origin, elevated systemic levels of the physiological agonists for
b-ARs epinephrine and norepinephrine may additionally stimulate
this pathway. This interpretation is in accord with recent reports that
have emphasized an important role of these stress hormones in the
aggressive behavior of adenocarcinoma of the colon (14), prostate
Fig. 5. Results of CRE-luciferase reporter assays in HPL1D (A) and NCI-
H322 (B) cells. Isoproterenol and NNK signiﬁcantly (P , 0.001) induced
CRE-luciferase while exposure to both agents had additive effects. GABA
completely inhibited the inductions of CRE-luciferase, an effect disinhibited
by siRNA knockdown of the GABABR. Data are mean values and standard
deviationof three replicateassaysconducted underidenticalconditions.Data
signiﬁcantly (P , 0.001) different from controls are identiﬁed by asterisk.
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1983(13), stomach (16), mammary gland (31) and ovary (17). Moreover,
non-genomic estrogen signaling via the estrogen receptor beta also
stimulates cAMP signaling and has been shown to cooperate with
NNK-induced b1-AR signaling in HPL1D cells (9). In conjunction
with these cited publications, our ﬁndings imply that environmental
and lifestyle factors that reduce GABA signaling and enhance
G-protein-coupled receptor-mediated cAMP signaling are risk factors
for the development of PAC and contribute signiﬁcantly to the
aggressive behavior of this cancer. In turn, the hitherto neglected in-
ﬂuence of stimulatory and inhibitory neurotransmitter signaling ap-
pears to be a promising target for the marker-guided prevention and
therapy of PAC.
GABABR agonists are routinely prescribed for the treatment of
muscle spasms due to spinal injuries, whereas GABA is widely used
as a dietary supplement to reduce anxiety and sleeplessness. The
concentrations of GABA and baclophen used in the current study
are within the range of systemic concentrations at the maximum rec-
ommended dosages for these agents in people. Precautions taking into
consideration the inhibitory effects of GABA-ergic agents on the
central nervous system would thus be similar as with their current
usage if they were used as anticancer drugs. However, the potential
exploitation of inhibitory GABABR signaling for the prevention or
adjuvant therapy of small airway-derived PAC will require the careful
monitoring of patients for pulmonary GABA levels and perhaps sys-
temic cAMP levels. Environmental and lifestyle factors as well as
diet, dietary supplements, drug treatments, stress and preexisting
non-neoplastic diseases can profoundly modulate cell and tissue lev-
els of GABA and cAMP, the number and sensitivity of GABARs as
well as Gas-coupled receptors, including the b-ARs, that stimulate
cAMP signaling. Large intraindividual differences in tissue GABA
levels and responsiveness to agonists for GABABRs are therefore to
be expected. The literature on the expression and function of GABA
and its receptors in neoplastic diseases reﬂects this diversity. A recent
publication from our laboratory thus reported underexpression of
GABA in 29 of 30 investigated tissue arrays from human pancreatic
ductal adenocarcinomas (PDACs) and GABABR-mediated inhibition
of cAMP-dependent transactivation of the EGFR pathway, cell pro-
liferation and cell migration in immortalized human pancreatic duct
epithelial cells and in human PDAC cell lines Panc-1 and BXPC-3
(32). In contrast, a Japanese laboratory published at about the same
time overexpression of GABA in 5 of 15 investigated tissue samples
from the same histological type of pancreatic cancer that was
Fig. 6. Western blots showing the induction of p-ERK1/2 in HPL1D (A) and NCI-H322 (B) cells by isoproterenol and the inhibition of these responses by GABA
or baclophen. The GABABR antagonist CGP-35348 blocked the inhibitory effects of GABA. Data in the graphs are mean values and standard deviations of ﬁve
densitometric readings per band. Data signiﬁcantly (P , 0.001) different from controls are identiﬁed by asterisk in both graphs.
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1984associated with overexpression of the pi subunit of the GABAAR (33).
Moreover, these investigators showed that two of seven investigated
human PDAC cell lines overexpressed this GABAAR subunit and
were stimulated in their growth by GABA, whereas the remaining
cell lines were not. Unfortunately, the responses to GABA of the ﬁve
PDAC cell lines without overexpressed GABAA-pi (including Panc-1
used in our study) were not shown although it was mentioned that they
were not stimulated by GABA (33). Differences in GABA contents in
a typical Western diet as opposed to a typical Asian diet due to the
high GABA contents in rice (34) may have contributed to the high
GABA levels observed in PDACs by the Japanese group. In addition,
the described overexpression of the GABAAR, which unlike the in-
hibitory GABABR mediates excitatory responses to GABA, may have
reversed the effects of GABA from inhibitory to stimulatory. Similar
discrepancies have been reported for colon cancer with GABA over-
expression reported as an indication that GABA signaling may con-
tribute to the carcinogenic process and GABA-ergic agonists may be
of use for cancer intervention (35), whereas others have reported in-
hibition of colon cancer cell migration by GABA (36). In conjunction
with our current data, these ﬁndings emphasize the need for marker-
guided cancer intervention as the histopathology classiﬁcation of can-
cer fails to provide reliable information on the presence or absence of
hyperactive or hypoactive regulatory pathways that may be suitable
drug targets in individual cases.
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